Top Markets
Coin of the day
Elevation Oncology, Inc. Elevation Oncology, Inc.

Elevation Oncology, Inc.

ELEV
Rank in Stocks #29359
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company... Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
Share Price
$0.365
Last synced: 2025-08-01
Market Cap
$21.54M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Elevation Oncology, Inc. (ELEV)

Category

P/S ratio for Elevation Oncology, Inc. (ELEV)
P/S ratio as of 2026 TTM: 0
According to Elevation Oncology, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Elevation Oncology, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH